Abstract:Predictive value of therapeutic monitoring with plasma Epstein-Barr virus DNA in Extranodal NK/T cell lymphoma, nasal type Background: Predictive tumor markers are essential for extranodal NK/T cell lymphoma, nasal type (ENKTL), which pursues an aggressive clinical course with poorer prognosis. This prospective study was conducted to evaluate the dynamic monitoring value of circulating EBV DNA concentration for the prediction of ENKL during treatment. Method: Patients with untreated, centrally reviewed diagnosis of ENKTL were included in our study. Plasma Epstein-Barr virus (EBV) DNA levels were collected before and/or every 2 cycles of chemotherapies for circulating EBV DNA measurement by a real-time PCR assay. Result: From Jan 2002 to Aug 2012, 113 newly diagnostic ENKTL patients enrolled. The positive rate of circulating EBV DNA is 61.9% (70/113) with a median concentration of 1.21×103copies/ml. Patients who had initial positive circulating EBV-DNA had more lymph nodes invasion, higher IPI and KPI score. The more advance of the stage, the higher rate of the circulating EBV-DNA positive. When divided the positive group as low and high-dose ones by the cut-off value as 2×104copies/ml, the CR rate of the high-dose group is much lower and the 5-year OS is significantly better than the low-dose group and the negative group. After two cycles of chemotherapy, 45 patients were tested circulating EBV-DNA and 53.33% (24/45) patients became negative EBV-DNA candidates. There were 87.5% (21/24) patients obtained complete remission at the end of the treatment, comparing as 42.86% (9/21) in the still positive EBV-DNA groups(P= 0.002). There is a tendency that the patients whose circulating EBV-DNA become negative after two cycles will have better prognosis (5-year OS: 75% vs 46%, P=0.074). The similar situation of CR rate and OS happened in the EBV-DNA detection of completion of total chemotherapy. 7 of 13 relapsed pts of ＞1×103copies/ml EBV-DNA at the time of recurrent, and the survival outcome was dismal for them compared to the other 6 pts of ≤1×103copies/ml（5- year OS: 0% vs 80%, P=0.001） Conclusion: Circulating EBV-DNA level can predict the efficacy of treatment as a dynamic marker of ENKL. Patients with early positive detection of EBV-DNA after 2 cycles of chemotherapy maybe received more aggressive treatments. Disclosures No relevant conflicts of interest to declare.

Post-Treatment Plasma Ebv-Dna Positivity Predicts Early Relapse and Poor Prognosis for Patients with Extranodal Nk/T Cell Lymphoma in the Era of Asparaginase

Clinical Implications Of Plasma Epstein-Barr Virus Dna In Early-Stage Extranodal Nasal-Type Nk/T-Cell Lymphoma Patients Receiving Primary Radiotherapy

High Post-Treatment Serum Levels of Soluble Programmed Cell Death Ligand 1 Predict Early Relapse and Poor Prognosis in Extranodal NK/T Cell Lymphoma Patients.

CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase

Predictive Value of Therapeutic Monitoring with Plasma Epstein-Barr Virus DNA in Extranodal NK/T Cell Lymphoma, Nasal Type

The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis

Prognostic Impact of Circulating Epstein-Barr Virus (EBV) DNA Concentration and EBV Serology in 125 Extranodal NK/T Cell Lymphoma, Nasal Type (ENKL) Patients

Early Negative Circulating EBV DNA As Prediction of Survival in Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL).

Clinical Significance of Plasma Epstein-Barr Virus DNA in Peripheral T-Cell Lymphomas.

Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome

Plasma Epstein-Barr Virus DNA Level Strongly Predicts Survival in Metastatic/recurrent Nasopharyngeal Carcinoma Treated with Palliative Chemotherapy.

Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.

Challenges in overcoming advanced-stage or relapsed refractory extranodal NK/T-cell lymphoma: meta-analysis of individual patient data

Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.

Plasma Epstein-Barr Virus DNA Load after Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma

Manifestation and Prognostic Value of EBV Serology in Nasal/nasopharyngeal T and NK-cell Lymphomas.

The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.

Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma

Spontaneous Remission Of Residual Post-Therapy Plasma Epstein-Barr Virus Dna And Its Prognostic Implication In Nasopharyngeal Carcinoma: A Large-Scale, Big-Data Intelligence Platform-Based Analysis

Prognostic implications of circulating Epstein–Barr virus DNA for extranodal natural killer/T-cell lymphoma, nasal type: a meta-analysis

Increased Serum Levels of Interleukin-10 Predict Poor Prognosis in Extranodal Natural Killer/t-Cell Lymphoma Patients Receiving Asparaginase-Based Chemotherapy